CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already ...
Phase 3
Norwalk, Connecticut, United States and 18 other locations
cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objecti ...
Phase 3
Stony Brook, New York, United States and 29 other locations
of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...
Phase 3
New Britain, Connecticut, United States and 125 other locations
efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian...
Phase 2
Danbury, Connecticut, United States and 20 other locations
the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...
Phase 2
New Haven, Connecticut, United States and 46 other locations
positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 pri...
Phase 2
New Haven, Connecticut, United States and 70 other locations
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian...
Phase 2
New Haven, Connecticut, United States and 19 other locations
letrozole is an effective treatment for people with low-grade serous ovarian cancer (LGSOC). The researchers will also look at the ...
Phase 2
Commack, New York, United States and 7 other locations
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....
Phase 3
New Haven, Connecticut, United States and 176 other locations
phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be...
Phase 1
New Haven, Connecticut, United States and 22 other locations
Clinical trials
Research sites
Resources
Legal